Haemonetics HAE Remeasurement of contingent consideration
Remeasurement of contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept hae:BusinessCombinationContingentConsiderationArrangementsIncreaseDecreaseOfContingentConsiderationLiability.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's remeasurement of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's remeasurement of contingent consideration?
- Haemonetics (HAE) reported remeasurement of contingent consideration of -$469.75K in Q1 2026.
- How has Haemonetics's remeasurement of contingent consideration changed year-over-year?
- Haemonetics's remeasurement of contingent consideration increased by 91.8% year-over-year, from -$5.76M to -$469.75K.
- What is the long-term trend for Haemonetics's remeasurement of contingent consideration?
- Over 3 years (2023 to 2026), Haemonetics's remeasurement of contingent consideration has grown at a 55.1% compound annual growth rate (CAGR), from -$504K to -$1.88M.
- What does remeasurement of contingent consideration mean?
- This represents the adjustment to the estimated fair value of earn-out payments or performance-based obligations related to past acquisitions. Changes in this value reflect updates to management's expectations regarding the achievement of specific financial or operational milestones by acquired entities. It serves as an indicator of acquisition performance and integration success.